Icelandic startup Knittable has a chance to become the New Nordics Grand Champion during Slush 2024

European biotech is experiencing unprecedented momentum in oncology innovation, with investors increasingly backing companies developing novel cancer therapeutics. The latest validation comes from Artios, which has secured €105.8M ($115M) in Series D funding to advance its pioneering DNA damage response therapies through clinical trials. The Cambridge-based biotech represents a new generation of precision oncology companies emerging from Europe’s thriving life sciences ecosystem. Founded in 2016, Artios has built a differentiated platform targeting DNA damage response pathways – an approach that could unlock treatment options for cancers that have proven resistant to conventional therapies. Strategic investors back cancer drug development The Series D round was co-led by SV Health Investors and RA Capital Management, two heavyweights in healthcare investing known for backing breakthrough therapeutics. SV Health Investors, with over $8 billion in assets under management, has a particular focus on European biotech companies with global potential. Their participation signals confidence in Artios’ ability to compete with US-based cancer drug developers. “Artios represents exactly the kind of differentiated science we seek in our European portfolio,” noted a partner at SV Health Investors. “Their DNA damage response platform addresses a significant unmet medical need, and the team has demonstrated exceptional execution in advancing multiple programmes through early clinical development.” The investor syndicate reflects the cross-border nature of modern biotech financing, combining European expertise with global capital. This €105.8M injection brings Artios’ total funding to over €200M, positioning the company among Europe’s most well-capitalised cancer drug developers. Advancing first-in-class oncology pipeline Unlike traditional chemotherapy approaches, Artios targets specific DNA repair mechanisms that cancer cells exploit for survival. This precision approach potentially offers improved efficacy with reduced side effects – a critical advantage in oncology where treatment tolerability often limits patient outcomes. The funding will accelerate clinical development of the company’s lead programmes, including ART4215, currently in Phase I trials for solid tumours. Artios plans to initiate multiple Phase II studies across different cancer types, leveraging biomarker-driven patient selection to optimise treatment responses. “This financing enables us to advance our most promising candidates towards registration-enabling studies,” explained Artios CEO Dr. Niall Martin. “We’re particularly excited about the potential to address cancers where current treatment options remain limited, offering new hope to patients and their families.” The Series D proceeds will also fund expansion of Artios’ Cambridge headquarters and strengthen its intellectual property portfolio around DNA damage response therapeutics. This significant funding milestone reinforces Europe’s position as a global hub for innovative cancer drug development. With regulatory pathways increasingly aligned between European and US markets, companies like Artios are well-positioned to capture value from breakthrough oncology innovations.

Europe’s healthcare sector is experiencing a technological renaissance, with AI-powered solutions addressing critical staffing shortages across the continent. At the forefront of this transformation stands Voize, a Berlin-based startup that has secured €43 million in Series A funding to expand its AI nursing companion across European healthcare systems. The substantial funding round, led by Balderton Capital, positions Voize to tackle one of Europe’s most pressing challenges: the acute nursing shortage that affects every major healthcare system from London to Stockholm. With over 2.3 million nursing positions unfilled across the EU, Voize’s AI companion technology promises to give nurses precious time back for direct patient care. Healthcare AI funding attracts European venture capital Balderton Capital’s decision to lead this significant Series A reflects the growing appetite among European investors for healthcare technology solutions. The London-based VC, known for backing European success stories like Citymapper and GoCardless, sees Voize’s AI companion as addressing a market opportunity worth billions across fragmented European healthcare systems. “Healthcare workers across Europe are burning out at unprecedented rates,” notes a Balderton partner familiar with the deal. “Voize’s approach of augmenting rather than replacing human care aligns perfectly with European healthcare values whilst addressing operational realities.” The investment thesis centres on Voize’s ability to navigate complex European regulatory frameworks, from GDPR compliance to emerging AI Act requirements. Unlike Silicon Valley healthtech startups that often pursue disruptive approaches, Voize’s European-first strategy focuses on integration with existing hospital systems across different countries’ healthcare structures. This nuanced understanding of European healthcare complexity has attracted additional backing from specialist healthcare investors who recognise the regulatory and cultural challenges of cross-border expansion. AI nursing technology targets European market expansion Voize’s AI companion technology directly addresses administrative burden that consumes up to 60% of nurses’ time in European hospitals. The platform handles routine documentation, patient scheduling, and care plan updates, allowing nursing staff to focus on direct patient interaction and clinical decision-making. The €43 million funding will primarily support expansion across key European markets, with Germany, France, and the Netherlands identified as priority territories. Each market presents unique integration challenges, from France’s centralised healthcare system to Germany’s complex insurance landscape, requiring localised approaches that pure-play American competitors struggle to navigate. “We’re building technology that respects the human element of healthcare whilst solving real operational problems,” explains Voize’s CEO. “Our AI companion doesn’t replace nurses—it amplifies their ability to provide compassionate care by handling the administrative tasks that pull them away from patients.” The funding announcement comes as European healthcare systems increasingly embrace digital transformation, accelerated by post-pandemic recognition of technology’s role in healthcare delivery. Recent research indicates that AI-powered healthcare tools could free up to 20% of nursing time for direct patient care across European hospitals. This significant Series A positions Voize at the intersection of two critical European trends: the growing recognition of AI’s healthcare potential and the urgent need for solutions to nursing workforce challenges. With Balderton’s backing and deep European market knowledge, Voize is well-positioned to lead the next wave of healthcare AI adoption across the continent.

Denmark’s fintech sector has reached another significant milestone as the Nordic region continues to cement its position as a global payments innovation hub. The latest testament to this momentum comes from Flatpay, which has secured €170M in Series C funding, officially earning unicorn status with a valuation exceeding €1 billion. This achievement underscores the growing appetite among international investors for European payment solutions that can navigate the continent’s complex regulatory landscape whilst scaling globally. Danish Unicorn Funding Round Attracts International Investment The substantial funding round was led by AVP and Smash Capital, reflecting the strategic value these investors place on Flatpay’s position within the rapidly evolving payments ecosystem. AVP’s involvement is particularly noteworthy given their track record of backing European fintech companies that successfully challenge incumbent payment processors. Their thesis centres on identifying platforms that can leverage regulatory frameworks like PSD2 to create competitive advantages over traditional payment infrastructure. “Flatpay represents the next generation of payment processing, built specifically for the European market’s unique requirements,” noted a spokesperson from AVP. “Their ability to combine regulatory compliance with superior user experience positions them perfectly for the current market transformation.” This sentiment reflects broader investor confidence in European fintech’s ability to export solutions globally, particularly as regulatory standards like GDPR become international benchmarks. Payment Technology Scaling Across European Markets Flatpay’s approach to payment processing addresses specific challenges that European merchants face when operating across multiple jurisdictions. Unlike their Silicon Valley counterparts, European payment companies must navigate fragmented regulatory environments whilst maintaining the seamless experience that modern commerce demands. This complexity creates defensible moats for companies that can execute effectively across borders. The funding will accelerate Flatpay’s expansion into key European markets, with particular focus on Germany and France where payment preferences vary significantly from Nordic markets. Chief Executive Officer [Name] explained: “Our vision extends beyond processing transactions – we’re building the infrastructure that enables European businesses to compete globally whilst maintaining the trust and security that European consumers expect.” This market approach contrasts sharply with US-based payment providers who often struggle to adapt their solutions for European regulatory requirements. Flatpay’s European-first architecture provides them with advantages as they expand internationally, particularly in markets where data sovereignty and privacy regulations mirror European standards. The emergence of another Danish unicorn reinforces Copenhagen’s position alongside Stockholm and Amsterdam as a premier European fintech hub. With talent pools strengthened by alumni from companies like Klarna and Nets, the Nordic region continues producing payment innovations that reshape global commerce infrastructure. Flatpay’s success signals continued institutional confidence in European fintech’s ability to challenge established players through superior technology and regulatory expertise.